Tranilast for IPF recommended for orphan drug designation in EU
A committee of the European Medicines Agency (EMA) is recommending orphan drug status — a designation that aims to speed therapy development in rare diseases — for tranilast, the active ingredient in NXP002, an inhaled formulation from Nuformix for treating idiopathic pulmonary fibrosis (IPF). A decision by the…